SGMO vs. MYGN, VSTM, EBS, LXRX, XOMA, CBIO, VNDA, CDXS, IRWD, and ACHV
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Myriad Genetics (MYGN), Verastem (VSTM), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), and Achieve Life Sciences (ACHV). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs. Its Competitors
Sangamo Therapeutics (NASDAQ:SGMO) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.
Sangamo Therapeutics presently has a consensus target price of $4.50, suggesting a potential upside of 722.37%. Myriad Genetics has a consensus target price of $12.45, suggesting a potential upside of 88.42%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Sangamo Therapeutics is more favorable than Myriad Genetics.
Sangamo Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Myriad Genetics had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 7 mentions for Myriad Genetics and 4 mentions for Sangamo Therapeutics. Myriad Genetics' average media sentiment score of 1.09 beat Sangamo Therapeutics' score of 0.50 indicating that Myriad Genetics is being referred to more favorably in the news media.
Sangamo Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 2.4% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Myriad Genetics has a net margin of -47.45% compared to Sangamo Therapeutics' net margin of -77.48%. Myriad Genetics' return on equity of -5.17% beat Sangamo Therapeutics' return on equity.
Summary
Myriad Genetics beats Sangamo Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SGMO) was last updated on 9/6/2025 by MarketBeat.com Staff
Free SGMO Stock Alerts